VERAXA Biotech Appoints Raju Willener as CFO to Drive Capital Strategy and Pipeline Development

VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener, who brings over three decades of international financial leadership experience, will report to CEO and Co-Founder Christoph Antz, Ph.D. His role is expected to be pivotal in supporting the company's capital strategy, exploring strategic opportunities, and advancing its proprietary BiTAC(R) technology platform and oncology pipeline.

Willener's extensive career spans global capital markets, investment banking, corporate finance, asset management, and strategic leadership. Prior to joining VERAXA, he served as director of corporate development at Exentis Group AG, later being appointed CFO in 2025. There, he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions managing corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.

This appointment comes at a critical juncture for VERAXA as it seeks to advance its pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative antibody formats. The company's BiTAC technology, developed from scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), is central to its mission of building a premier engine for next-generation antibody therapeutics. Willener's financial acumen is likely to enhance VERAXA's ability to secure funding, forge strategic partnerships, and navigate the complexities of clinical development.

In a statement, CEO Christoph Antz expressed confidence in Willener's ability to contribute to the company's growth, highlighting his proven track record in corporate development and finance. The market has responded positively to the news, reflecting optimism about VERAXA's strategic direction. As the company continues to progress its clinical programs, the addition of a seasoned CFO like Willener is seen as a strategic move to strengthen its financial foundation and accelerate its path toward commercialization.

For more information on VERAXA Biotech and its pipeline, visit the company's newsroom at https://ibn.fm/VRXA. To view the full press release, visit https://nnw.fm/jcHOU.

Forward-looking statements in this announcement involve risks and uncertainties, as detailed in VERAXA's filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent quarterly reports. The company undertakes no obligation to update these statements except as required by law.